RHJA
BCRX icon

Rice Hall James & Associates’s BioCryst Pharmaceuticals BCRX Stock Holding History

Rice Hall James & Associates’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.3M Buy
2,332,043
+101,938
+5% +$922K 1.14% 25
2026
Q1 		$21.2M Buy
2,230,105
+325,959
+17% +$2.53M 1.18% 25
2025
Q4 		$14.9M Buy
1,904,146
+23,757
+1% +$172K 0.82% 40
2025
Q3 		$14.3M Sell
1,880,389
-179,891
-9% -$1.5M 0.78% 40
2025
Q2 		$18.5M Buy
2,060,280
+32,712
+2% +$305K 0.99% 29
2025
Q1 		$15.2M Sell
2,027,568
-53,748
-3% -$434K 0.89% 32
2024
Q4 		$15.7M Sell
2,081,316
-82,427
-4% -$626K 0.86% 33
2024
Q3 		$16.4M Buy
2,163,743
+84,102
+4% +$639K 0.89% 28
2024
Q2 		$12.9M Sell
2,079,641
-71,904
-3% -$397K 0.77% 38
2024
Q1 		$10.9M Sell
2,151,545
-45,716
-2% -$257K 0.62% 45
2023
Q4 		$13.2M Sell
2,197,261
-78,377
-3% -$454K 0.76% 42
2023
Q3 		$16.1M Buy
2,275,638
+402,674
+21% +$2.89M 1.02% 23
2023
Q2 		$13.2M Buy
+1,872,964
New +$15M 0.75% 40

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Rice Hall James & Associates's BCRX Position: Q2 2026 in Review

Rice Hall James & Associates increased its BioCryst Pharmaceuticals (BCRX) stake by 4.6% in Q2 2026, buying an estimated $922K and bringing the position to 2,332,043 shares worth $23.3M. The position accounts for 1.14% of the portfolio, ranked #25.

Rice Hall James & Associates first reported a position in BCRX in Q2 2023 and has held it in 13 quarters since. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Rice Hall James & Associates held 2,332,043 shares of BioCryst Pharmaceuticals worth $23.3M as of Q2 2026.
  • Rice Hall James & Associates bought 101,938 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $922K.
  • BioCryst Pharmaceuticals made up 1.14% of Rice Hall James & Associates's portfolio in Q2 2026, its #25 holding.
  • Rice Hall James & Associates first reported a position in BioCryst Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • 319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Rice Hall James & Associates's 13F filing for Q2 2026, filed 7 Aug 2026.